Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Itopride

Itopride

Itopride structure

Itopride 

structure
  • CAS No:

    122898-67-3

  • Formula:

    C20H26N2O4

  • Chemical Name:

    Itopride

  • Synonyms:

    Benzamide,N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-;N-[[4-[2-(Dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide;Itopride;N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide;2099691-88-8

  • Categories:

    Active Pharmaceutical Ingredients  >  Digestive System Drugs

Description

N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide is a member of benzamides.|Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

Itopride Basic Attributes

358.43

358.43

1312995-182-4

81BMQ80QRL

759643

DTXSID7048320

A - Alimentary tract and metabolism

2924299090

Characteristics

60

2.43

1.122±0.06 g/cm3(Predicted)

109-110.5 °C @ Solvent: Toluene

510.1±50.0 °C(Predicted)

262.3±30.1 °C

1.552

H2O: 18 g/100 mL (20 ºC)

Safety Information

R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R36/37/38:Irritating to eyes, respiratory system and skin .

S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36:Wear suitable protective clothing .

T,Xi,Xn

P273, P391, P501

H400

Drug Information

Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).

Flavin-containing monooxygenase (FMO) is involved in N-oxygenation, the major metabolic pathway of itopride (PMID: 10997945).

Itopride has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity. It is well established that M3 receptors exist on the smooth muscle layer throughout the gut and acetylcholine (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M3 receptors. The enzyme AChE hydrolyses the released ACh, inactivates it and thus inhibits the gastric motility leading to various digestive disorders. Besides ACh, dopamine is present in significant amounts in the gastrointestinal tract and has several inhibitory effects on gastrointestinal motility, including reduction of lower esophageal sphincter and intragastric pressure. These effects appear to result from suppression of ACh release from the myenteric motor neurons and are mediated by the D2 subtype of dopamine receptors. Itopride, by virtue of its dopamine D2 receptor antagonism, removes the inhibitory effects on Ach release. It also inhibits the enzyme AchE which prevents the degradation of ACh. The net effect is an increase in ACh concentration, which in turn, promotes gastric motility, increases the lower esophageal sphincter pressure, accelerates gastric emptying and improves gastro-duodenal coordination. This dual mode of action of Itopride is unique and different from the actions of other prokinetic agents available in the market.

itopride

Itopride Use and Manufacturing

dyspepsia therapy

Computed Properties

Molecular Weight:358.4
XLogP3:2.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:9
Exact Mass:358.18925731
Monoisotopic Mass:358.18925731
Topological Polar Surface Area:60
Heavy Atom Count:26
Complexity:411
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.